Clinical trial
Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With…
NCT00102622 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00102622 |
|---|---|
| Title | Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer |
| Official title | Phase I of Phase I/II Randomized Study of Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Institutes of Health (NIH) NIH National Cancer Institute (NCI) |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Biological, Drug |
| Interventions | Intraperitoneal tgDCC-E1A, Paclitaxel |
| Enrollment | 18 |
| Start date | Dec 1, 2004 |
| Primary completion | Jul 1, 2012 |
| Completion | Jul 1, 2012 |
| First posted | Feb 1, 2005 |
| Last update posted | Nov 13, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: